Silence Therapeutics promotes Jorg Kaufmann
pharmafile | May 21, 2010 | Appointment | Research and Development | Silence Therapeutics, appointment, research and development, rnai
Jorg Kaufmann has been made vice president of research at UK biotech company Silence Therapeutics.
He previously served as senior director of technologies, and in his new role he will play a key role overseeing Silence’s range of RNA interference (RNAi) research activities.
Silence’s chief scientific officer Klaus Giese said: “In his time at Silence Dr. Kaufmann has proven himself a valued member of our research team, playing a significant role in advancing a number of our novel RNAi technologies including proprietary RNAi delivery platforms and innovative approaches siRNA structural modification.
“The ongoing successes achieved by our team of scientists in Berlin combined with the consolidation of all research activities to our Berlin location, has created a need to continue to strengthen our research organisation.”
Jorg has more than 13 years of biotechnology industry experience in both the US and Europe. Since joining Silence in 2000, he has served as both senior and associate director, technologies, and prior to joining Silence was a senior scientist at Chiron.
He will continue to be based at Silence’s Berlin research centre, where the company recently announced it is consolidating all research activities related to its novel RNAi therapeutic platforms.
Related Content
Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the …
AstraZeneca to leverage Silence Therapeutics’ siRNA expertise in $480mn deal
Silence Therapeutics has revealed it has struck a new collaboration with AstraZeneca which will trigger …
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …